Mineralys Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 11 →Insiders5 insiders bought $8.8M in 2 open-market buys. 7 insiders sold $78.3M, 47 of 70 sales on a 10b5-1 plan.→HoldersCatalys Pacific 8.9%Ra 8.7%BlackRock 6.7%→PeersClosest companies: QTTB, NUVB, PRAX→
From the filings
Figures
- Net income
- −$349.6Mlast 12 months
- Operating cash flow
- −$136.4Mlast 12 months
- Cash and equivalents
- $138.3Mat the last balance sheet
- Total debt
- $100,000at the last balance sheet
- Shares outstanding
- 88.4M shareson issue